Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ata Erdogan"'
Autor:
Charles J. Davidson, Matthew E. Harinstein, Ata Erdogan, Karen Pieper, Stephanie Gagnon, Sheridan N. Meyers, Nirat Beohar
Publikováno v:
Journal of Interventional Cardiology. 23:528-545
Objective: The purpose of this systematic review was to evaluate differences in lesion-specific outcomes with the “off-label” use of drug-eluting stents (DES) versus bare metal stents (BMS). Methods: MEDLINE, PubMed, the Cochrane databases, and o
Autor:
Nirat, Beohar, Sheridan N, Meyers, Ata, Erdogan, Matthew E, Harinstein, Karen, Pieper, Stephanie, Gagnon, Charles J, Davidson
Publikováno v:
Journal of interventional cardiology. 23(6)
The purpose of this systematic review was to evaluate differences in lesion-specific outcomes with the "off-label" use of drug-eluting stents (DES) versus bare metal stents (BMS).MEDLINE, PubMed, the Cochrane databases, and other Web were searched fo
Autor:
Ata, Erdogan, Charles J, Davidson
Publikováno v:
Reviews in cardiovascular medicine. 4
In patients with well-preserved renal function, the choice of contrast agent appears to have little impact on the development of contrast-induced nephropathy (CIN). However, in patients with underlying renal insufficiency and diabetes mellitus, it ha
Autor:
Robert O. Bonow, Hani N. Sabbah, John R. Teerlink, Ata Erdogan, Mihai Gheorghiade, Morton J. Kern, Daniel C. Lee, Nirat Beohar
Publikováno v:
Journal of the American College of Cardiology. (1):13-16
Acute heart failure syndromes (AHFS), with a high post-discharge mortality and rehospitalization rate, represent a significant public health burden. The treatment of patients hospitalized with AHFS often includes the use of vasoactive medications suc
Autor:
Zankhana Raval, Mihai Gheorghiade, Nina Kay, James D. Flaherty, Matthew E. Harinstein, Ata Erdogan, M. Abecassis, Sanjiv J. Shah, Anton I. Skaro, Andre DeWolf, Oren K. Fix
Publikováno v:
Journal of the American College of Cardiology. (3):223-231
Liver transplantation (LT) candidates today are increasingly older, have greater medical acuity, and have more cardiovascular comorbidities than ever before. Steadily rising model for end-stage liver disease (MELD) scores at the time of transplant, r